HK1095332A1 - Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof - Google Patents

Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof

Info

Publication number
HK1095332A1
HK1095332A1 HK07100995.8A HK07100995A HK1095332A1 HK 1095332 A1 HK1095332 A1 HK 1095332A1 HK 07100995 A HK07100995 A HK 07100995A HK 1095332 A1 HK1095332 A1 HK 1095332A1
Authority
HK
Hong Kong
Prior art keywords
hcv
dna
compositions
methods
cationic microparticles
Prior art date
Application number
HK07100995.8A
Other languages
English (en)
Inventor
Derek O'hagan
Michael Houghton
Manmohan Singh
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of HK1095332A1 publication Critical patent/HK1095332A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK07100995.8A 2003-04-25 2007-01-26 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof HK1095332A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46584103P 2003-04-25 2003-04-25
PCT/US2004/012510 WO2004096136A2 (fr) 2003-04-25 2004-04-23 Compositions de microparticules cationiques et d'adn de vhc e1, e2 et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
HK1095332A1 true HK1095332A1 (en) 2007-05-04

Family

ID=33418301

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100995.8A HK1095332A1 (en) 2003-04-25 2007-01-26 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof

Country Status (10)

Country Link
US (2) US20070264285A1 (fr)
EP (1) EP1622566A4 (fr)
JP (1) JP2006524698A (fr)
CN (1) CN1809584B (fr)
AU (1) AU2004233851B2 (fr)
CA (1) CA2523266A1 (fr)
HK (1) HK1095332A1 (fr)
NZ (1) NZ543343A (fr)
RU (1) RU2364419C2 (fr)
WO (1) WO2004096136A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0602637D0 (en) * 2006-02-09 2006-03-22 Glaxo Group Ltd Novel process
RU2625546C2 (ru) * 2010-07-06 2017-07-14 Новартис Аг Катионные эмульсии "масло-в-воде"
EP2765982A1 (fr) * 2011-10-11 2014-08-20 Hans Kosak Diméthylsulfoxyde utilisé comme solvant pour des acides nucléiques
RU2675108C2 (ru) * 2015-06-15 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996004301A2 (fr) * 1994-07-29 1996-02-15 Chiron Corporation Nouveaux polypeptides a troncature e1 et e2 de l'hepatite c et procede d'obtention de ces derniers
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
WO1999030737A1 (fr) * 1997-12-16 1999-06-24 Chiron Corporation Utilisation de microparticules combinees avec des emulsions huile-dans-eau submicroniques
AU5677399A (en) * 1998-08-20 2000-03-14 Wistar Institute Of Anatomy And Biology, The Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
EP2286792A1 (fr) * 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions avec une surface adsorbante, comprenant une émulsion de microgouttes
ATE413190T1 (de) * 1999-12-01 2008-11-15 Novartis Vaccines & Diagnostic Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)
WO2002026209A2 (fr) * 2000-09-28 2002-04-04 Chiron Corporation Microparticules de transport d'acides nucleiques heterologues
DE60125795T2 (de) * 2000-09-28 2007-10-18 Novartis Vaccines and Diagnostics, Inc., Emeryville Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
ES2399386T3 (es) * 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
CN1931365A (zh) * 2001-06-29 2007-03-21 希龙公司 Hcv e1e2疫苗组合物
AU2003287188A1 (en) * 2002-10-25 2004-05-25 Chiron Corporation Activation of hcv-specific cells

Also Published As

Publication number Publication date
RU2005136668A (ru) 2006-03-20
EP1622566A4 (fr) 2008-06-25
AU2004233851B2 (en) 2009-07-30
CA2523266A1 (fr) 2004-11-11
WO2004096136A2 (fr) 2004-11-11
NZ543343A (en) 2008-03-28
CN1809584A (zh) 2006-07-26
JP2006524698A (ja) 2006-11-02
US20070264285A1 (en) 2007-11-15
US20110177110A1 (en) 2011-07-21
EP1622566A2 (fr) 2006-02-08
AU2004233851A1 (en) 2004-11-11
CN1809584B (zh) 2010-12-01
RU2364419C2 (ru) 2009-08-20
WO2004096136A3 (fr) 2005-06-02

Similar Documents

Publication Publication Date Title
HK1110602A1 (en) Compositions and methods of using angiopoietin-like protein
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
IL219406A0 (en) Antiloading compositions and methods of selecting same
AU2003259735A8 (en) Small-mer compositions and methods of use
SG2009050212A (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
EP1639086A4 (fr) Arn interferases et leurs procedes d'utilisation
GB0411940D0 (en) Methods and compositions
HK1084949A1 (en) Arylvinylazacycloalkane compounds and methods of preparation and use thereof
EP1654379A4 (fr) Methodes et compositions permettant de renforcer l'expression et la purification de proteines
EP1701725A4 (fr) Methodes et compositions
EP1696910A4 (fr) Compositions et procedes pour traiter une fibrose
EP1786265A4 (fr) Nouvelles compositions et procedes de traitement
AU2003299441A8 (en) Nf-hev compositions and methods of use
IL174325A0 (en) Dna vaccine compositions and methods of use
GB0303609D0 (en) Novel therapeutic method and compositions
EP1633749A4 (fr) Composes de deazaflavine et leurs methodes d'utilisation
HK1095332A1 (en) Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
EP1625141A4 (fr) Compositions a base de grp94 et procedes d'utilisation associes
GB0324523D0 (en) Compositions and methods of treatment
EP1663124A4 (fr) Compositions antimicrobiennes et procedes d'utilisation
EP1583557A4 (fr) Compositions vaccinales et procedes
GB0327050D0 (en) Therapeutic methods compositions and uses
GB0303600D0 (en) Novel therapeutic method and compositions
AU2003300770A8 (en) Cardiolipin compositions their methods of preparation and use
EP1616020A4 (fr) Anticorps anti cr1 a immunogenicite reduite et methodes de traitement les utilisant

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150423